Amgen

Amgen

Yahoo Finance • 18 hours ago

Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) is shaking up the Dow Jones Industrial Average. The Google parent joined the famed index on June 29, replacing Verizon Communications and providing additional exposure to advertising, cloud computing... Full story

Yahoo Finance • 2 days ago

UBS, BofA, Jefferies Start Quantinuum With Buy Ratings On 'Full-Stack' Platform

Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform. Continue Reading... Full story

Yahoo Finance • 4 days ago

Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next.

On June 23, S&P Dow Jones Indices announced that Alphabet would be replacing Verizon Communications in the Dow Jones Industrial Average. Since 2020, seven of the Dow's 30 components have changed, including the additions of Honeywell Inter... Full story

Yahoo Finance • 5 days ago

FDA commissioner contenders down to three - report

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers * The Trump administration has narrowed its list of potential FDA commissioners down to three. * The finalists are senior Pentagon health official Stephen Ferrara;... Full story

Yahoo Finance • 5 days ago

Medicare GLP-1 Bridge: What to expect

[Injectable semaglutide pens for glucose control with a blue measuring tape on a clean background for weight loss and medical themes.] Eduardo Monroy Husillos/iStock via Getty Images Millions of Americans are set to gain access to certain... Full story

Yahoo Finance • 6 days ago

2 Healthcare Stocks to Consider Right Now and 1 We Brush Off

2 Healthcare Stocks to Consider Right Now and 1 We Brush Off From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited f... Full story

Yahoo Finance • 7 days ago

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers. Should inve... Full story

Yahoo Finance • 8 days ago

Organon and Henlius launch Prolia and Xgeva biosimilars in Canada

* Organon Canada (OGN [https://seekingalpha.com/symbol/OGN]) and Shanghai Henlius Biotech on Tuesday announced [https://seekingalpha.com/pr/20559842-organon-canada-and-henlius-expand-access-to-denosumab-treatments-with-launch-of-bildyos]... Full story

Yahoo Finance • 8 days ago

Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design

Dublin, June 23, 2026 (GLOBE NEWSWIRE) -- The "Women's Clinical Trials & CROs Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering. The report's release comes as the women's health research landscape undergoes... Full story

Yahoo Finance • 8 days ago

Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court

Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal s... Full story

Yahoo Finance • 11 days ago

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Key Points Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumo... Full story

Yahoo Finance • 15 days ago

Dow tops record high, and here’s how all 30 stocks rank according to SA Quant Ratings

[Dow Jones Stock Market Concept with Financial Graphs] The Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) reached a fresh record high on Monday, highlighting the strength of the market’s recent advance and extend... Full story

Yahoo Finance • 16 days ago

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and... Full story

Yahoo Finance • 19 days ago

Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight

This article first appeared on GuruFocus. Amgen (NASDAQ:AMGN) has moved to defend Tavneos, a rare disease drug that US regulators are trying to pull from the market, by bringing in the Duke Clinical Research Institute to review the study... Full story

Yahoo Finance • 20 days ago

Is Amgen Inc. (AMGN) A Good Stock To Buy Now?

Is AMGN a good stock to buy? We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.'s share was trading at $344.57 as of June 9th.... Full story

Yahoo Finance • 22 days ago

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support the idea that 2026 could be a “springboard year”, with revenue up 6% and EPS up 5% as growth products offset pat... Full story

Yahoo Finance • 22 days ago

2 S&P 500 Stocks with Competitive Advantages and 1 Facing Challenges

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds. Even among blue-chip stocks, not... Full story

Yahoo Finance • 23 days ago

Can MariTide Save Amgen Stock From Its Fading Blockbusters?

Trefis: AMGN Stock Insights The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days. In a week where the S&P 500 has stumbled, losing 2.6%, Amgen (AMGN) has been a... Full story

Yahoo Finance • 23 days ago

Amgen Reports New VESALIUS-CV Subgroup Results For Evolocumab In High-Risk Diabetes

(RTTNews) - Amgen Inc. (AMGN), a commercial-stage biotechnology company, reported new subgroup analyses from the phase 3 VESALIUS-CV trial of its PCSK9 inhibitor, Evolocumab (Repatha), for people living with high-risk diabetes and elevated... Full story

Yahoo Finance • 23 days ago

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS,... Full story